Cargando…

Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery

Since there were a few articles to report the treatment of severe pulmonary vasoconstriction induced by protamine in cardiac surgery, we described the use of epoprostenol to reverse this condition. A total of 5 cases of severe pulmonary vasoconstriction induced by protamine in cardiac surgery were r...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Zheng, Shen, Xin, Zhang, Yong-Jian, Li, Xiao-Gang, Gao, Yan-Feng, Tan, Jing, Yuan, Hui, Liu, Jing-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076185/
https://www.ncbi.nlm.nih.gov/pubmed/29995750
http://dx.doi.org/10.1097/MD.0000000000010908
_version_ 1783344662374776832
author Guan, Zheng
Shen, Xin
Zhang, Yong-Jian
Li, Xiao-Gang
Gao, Yan-Feng
Tan, Jing
Yuan, Hui
Liu, Jing-Jie
author_facet Guan, Zheng
Shen, Xin
Zhang, Yong-Jian
Li, Xiao-Gang
Gao, Yan-Feng
Tan, Jing
Yuan, Hui
Liu, Jing-Jie
author_sort Guan, Zheng
collection PubMed
description Since there were a few articles to report the treatment of severe pulmonary vasoconstriction induced by protamine in cardiac surgery, we described the use of epoprostenol to reverse this condition. A total of 5 cases of severe pulmonary vasoconstriction induced by protamine in cardiac surgery were reviewed. The demographic, clinical data and treatment process were obtained. All the patients were followed up. Severe pulmonary vasoconstriction was occurred 4 to 10 minutes after protamine infusion. The primary sign was sudden hypotension, the pulmonary artery pressure was increased gradually, the arterial oxygen partial pressure was decreased in all the patients. Epoprostenol was infused via pulmonary artery catheter at dosage of 20 to 40 ng/kg·min in all the patients, 2 patients were underwent re-cardiac pulmonary bypass assistance. The hemodynamic instability status lasted 40 to 65 minutes respectively. All the patients were recovered uneventfully. All physicians should alert to the incidence of severe pulmonary vasoconstriction induced by protamine in cardiac surgery. Use epoprostenol through pulmonary artery catheter could treat pulmonary artery vasoconstriction effectively and safely.
format Online
Article
Text
id pubmed-6076185
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-60761852018-08-17 Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery Guan, Zheng Shen, Xin Zhang, Yong-Jian Li, Xiao-Gang Gao, Yan-Feng Tan, Jing Yuan, Hui Liu, Jing-Jie Medicine (Baltimore) Research Article Since there were a few articles to report the treatment of severe pulmonary vasoconstriction induced by protamine in cardiac surgery, we described the use of epoprostenol to reverse this condition. A total of 5 cases of severe pulmonary vasoconstriction induced by protamine in cardiac surgery were reviewed. The demographic, clinical data and treatment process were obtained. All the patients were followed up. Severe pulmonary vasoconstriction was occurred 4 to 10 minutes after protamine infusion. The primary sign was sudden hypotension, the pulmonary artery pressure was increased gradually, the arterial oxygen partial pressure was decreased in all the patients. Epoprostenol was infused via pulmonary artery catheter at dosage of 20 to 40 ng/kg·min in all the patients, 2 patients were underwent re-cardiac pulmonary bypass assistance. The hemodynamic instability status lasted 40 to 65 minutes respectively. All the patients were recovered uneventfully. All physicians should alert to the incidence of severe pulmonary vasoconstriction induced by protamine in cardiac surgery. Use epoprostenol through pulmonary artery catheter could treat pulmonary artery vasoconstriction effectively and safely. Wolters Kluwer Health 2018-07-13 /pmc/articles/PMC6076185/ /pubmed/29995750 http://dx.doi.org/10.1097/MD.0000000000010908 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Guan, Zheng
Shen, Xin
Zhang, Yong-Jian
Li, Xiao-Gang
Gao, Yan-Feng
Tan, Jing
Yuan, Hui
Liu, Jing-Jie
Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
title Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
title_full Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
title_fullStr Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
title_full_unstemmed Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
title_short Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
title_sort use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076185/
https://www.ncbi.nlm.nih.gov/pubmed/29995750
http://dx.doi.org/10.1097/MD.0000000000010908
work_keys_str_mv AT guanzheng useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery
AT shenxin useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery
AT zhangyongjian useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery
AT lixiaogang useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery
AT gaoyanfeng useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery
AT tanjing useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery
AT yuanhui useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery
AT liujingjie useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery